




C

EGYPTIAN ACADEMIC JOURNAL OF

BIOLOGICAL SCIENCES

PHYSIOLOGY & MOLECULAR BIOLOGY



ISSN
2090-0767

WWW.EAJBS.EG.NET

Vol. 15 No. 1 (2023)



Epidemiological, Clinical, and Pathological Characteristics of Gastric Carcinoma in The Northwest Region of Algeria: A Single Center Study

Cherifi Yasmina^{1,2}, Haoud Khadidja¹, Drici Amine Mokhtar¹, Sasaa Elcherifa^{1,2}, Ouali Siheme¹, Kanoun Khedoudja^{1,2} and Djamilia Yekrou³.

- 1- Biology Department, Faculty of Natural Sciences and Life, Djillali Liabes University of Sidi-Bel-Abbes, BP No. 89 Sidi-Bel-Abbes 22000 Algeria.
- 2- Laboratory of Molecular Microbiology Health and Proteomics, Faculty of Natural Sciences and Life, Djillali Liabes University of Sidi-Bel-Abbes, BP No. 89 Sidi-Bel-Abbes 22000 Algeria.
- 3- Departement of medical oncology. Anti-cancer centre of Sidi Bel Abbes. Algeria.

*E-mail: cherifi.yasmina90@gmail.com

ARTICLE INFO

Article History

Received:29/1/2023

Accepted:24/2/2023

Available:28/2/2023

Keywords:

Gastric cancer (GC);
epidemiology;
Clinical
Characteristics;
Algerian Patients.

ABSTRACT

Introduction: Cancer of the stomach is a serious public health issue due to its frequency and severity. It is one of the most common causes of cancer-related death for both sexes and is a major contributor to the global burden of disease. To better understand the epidemiological, clinical, and pathological characteristics of gastric cancer in the Western Algerian region Sidi Bel Abbes, our study aimed to investigate the prevalence, risk factors, and clinical outcomes of gastric cancer in this region. **Methods:** The medical records of 131 patients with gastric cancer in the Sidi Bel Abbes region between January 2015 and December 2019 were reviewed retrospectively in order to gain insight into the epidemiology of gastric cancer in the region. **Result:** The results of this statistical analysis indicate that there is a male predominance in the cases studied and that the average age of the patients is 61.069 years. Histologically, carcinoma is the most common histological type (87.7%). 77.1% of cases were diagnosed in stages III and IV of TNM, and 46.6% of cases were found in the pyloric antrum. 38.2% of the cases had atrophic chronic gastritis as a precancerous lesion, and 16.8% had acute or chronic gastritis. **Conclusion:** The diagnosis of gastric cancer is often made at a late stage with a poor prognosis. However, in order to develop strategies for prevention and early detection, extensive research is still needed to identify the risk factors for gastric cancer.

INTRODUCTION

One of the most common types of cancer worldwide is stomach cancer. It is an aggressive disease with a poor five-year prognosis (Matsuoka *et al.*, 2018). According to the GLOBOCAN 2020 report, stomach cancer is the fourth leading cause of cancer deaths in both sexes, accounting for approximately 800,000 deaths (7.7% of all cancer deaths). According to Sung *et al.*, 2020, approximately 1.1 million new stomach cancer cases are expected in 2020 (representing 5.6% of all cancer cases).

A huge portion of gastric cancer occurs in developing countries. In contrast to the high incidence rate observed in East Asia (for example, Mongolia, Japan, and the Republic of Korea), northern Europe and northern America exhibit relatively low incidence rates that are comparable to those observed in African countries (Bray *et al.*, 2018). Algeria has a lower incidence of this disease than developed countries and slightly higher than the Maghreb countries (Hussein *et al.*, 2016). The purpose of this study was to establish an epidemiological profile of gastric adenocarcinoma in the north-western region of Algeria, to determine the frequency of stomach cancer, and to describe the clinical, biological, and pathological factors involved.

MATERIALS AND METHODS

Population:

A retrospective descriptive survey was conducted on 131 patients with gastric cancer admitted to the Anti-Cancer Center in Sidi Bel Abbes between January 2015 and December 2019. Anatomopathological and medical data from the patient's medical records were reviewed for the following: age, gender, type of neoplasia, personal, family, and surgical history. In this study, only patients with a confirmed pathological cell type and adequate medical records were included.

Statistical Analyses:

For the statistical analysis, data were summarized using rates and cross-tabulations. Graphs and tables were used to present the results. SPSS 22.0 (Statistical Package for the Social Sciences, IBM Corporation; Chicago, IL. August 2013) was

used to process and analyze all data.

RESULTS

There was a clear male predominant (67.34 percent of 84 patients) in the study, as well as a male-to-female ratio of 1.78. The average age of our patients ranged from 33 to 86 years was 61.069 ± 12.449 years (62.167 ± 11.898 years in men, 59.106 ± 13.283 years in women). The distribution of patients based on their age groups is presented in Figure 1.

Carcinoma made up 87.8% of the cases, a MALT lymphoma made up 7.6%, and a gastrointestinal stromal tumor made up 3.8%. In accordance with Lauren's classification, 42.7% of these carcinomas were of the intestinal type, followed by the mixed type and diffuse type of respective frequencies of 30.5% and 26.7% (Table 1).

There were 46.6% of tumor cases located in the antropyloric region, 32.8% in the fundus, and 15.3% in the cardia based on the tumor topography. According to Table 2, epigastralgia was the most commonly reported clinical sign (76.3%), followed by vomiting (71.0%), gastrointestinal bleeding (44.3%), and hematemesis (38.2%).

According to Table 3, we found the following precancerous lesions: 38.2% of cases were atrophic chronic gastritis, 16.8% were acute or chronic gastritis, 9.16% were gastric ulcers, 2.3% were partial gastrectomy stumps, and 7.6% were associated with a family history of gastric cancer. According to the findings of this study, smoking and *Helicobacter pylori* infection were the main risk factors.




Fig. 1: Age distribution of patients.

Table 1: Clinical and pathological characteristics of gastric cancer patients based on gender.

	Males (67.34%) N (%) or Mean±SD	Females (32.66%) N (%) or Mean±SD	Total N (%) or Mean±SD	P value
Age	62.167±11.898	59.106±13.283	61.069±12.449	0.839
Histologic type				0.117
Carcinoma	74 (88.1%)	41(87.2%)	115(87.8%)	
Gastrointestinal stromal tumor	5(6.0%)	0(0.0%)	5(3.8%)	
MALT lymphoma	4(4.8%)	6(12.8%)	10(7.6%)	
Neuro-endocrine	1(1.2%)	0(0.0%)	1(0.8%)	
Lauren's classification				0.466
Intestinal	39(46.4%)	17(36.2%)	56(42.7%)	
Diffuse	23(27.4%)	17(36.2%)	40 (30.5%)	
Mixed	22(26.2%)	13(27.7%)	35(26.7%)	
Pt				0.458
T1	12(14.3%)	3(6.4%)	15(11.5%)	
T2	14(16.7%)	11(23.4%)	25(19.1%)	
T3	45(53.6%)	27(57.4%)	72(55.0%)	
T4	13(15.5%)	6(12.8%)	19(14.5%)	
PN				0.645
N0	24(28.6%)	9(19.1%)	33(25.2%)	
N1	20(23.8%)	14(29.8%)	34(26.0%)	
N2	25(29.8%)	14(29.8%)	39(29.8%)	
N3	15(17.9%)	10(21.3%)	25(19.1%)	
Pm				0.558
M0	69(82.1%)	39(80.0%)	108(82.4%)	
M1	13(15.5%)	8(17.0%)	21(16%)	
M2	2(2.4%)	0(0.0%)	2(1.5%)	
TNM stage				0.514
I/II stages	20(23.8%)	10(21.2%)	30(22.9%)	
III/IV stages	64(76.2%)	37(78.7%)	101(77.1)	
Tumor topography				0.156
antropyloric	43 (51.2%)	18(38.3%)	61(46.6%)	
Cardia	15(17.9%)	5(10.6%)	20(15.3%)	0.271
Fundus	27(32.1%)	16(34.0%)	43(32.8%)	0.824
Corpus	5(6.0%)	2(4.3%)	7(5.3%)	0.679

Table2: The medical history of the patient.

Medical history	Number (%)
Personal history of tumor	2 (1.5%)
Family History of tumor gastric	10 (7.6%)
Family history of tumor	14(10.7%)
Gastric ulcer	30 (22.9%)
Atrophic chronic gastritis	50(38.2%)
Acute or Chronic gastritis	22(16.8%)
Partial gastrectomy stump	3(2.3%)
Helicobacter pylori infection	55(41.99%)
Tobacco	40(30.53%)
Alcohol	12(9.16%)

Table3: A description of the signs and symptoms.

Clinical signs	Number (%)
Epigastralgia	100(76.3%)
Vomiting	93(71.0%)
Gastrointestinal bleeding	58(44.3%)
Hematemesis	50(38.2%)
Asthenia	94(71.8%)
Abdominal pain	91(69.05%)

DISCUSSION

Associated with genetic and environmental factors, stomach cancer is a heterogeneous disease that has an extremely poor prognosis.

This study found an average age of 61.069 ± 12.449 years. Gastric cancer is considered by the majority of authors to be a disease affecting older men, which is in agreement with our findings (Elghali *et al.*, 2018; Behar *et al.*, 2021). In fact, the average age of patients with gastric cancer often varies between 60 and 80 years (Nagini, 2012).

In several studies, gastric cancer affects more men than women, which is consistent with our finding of 1.78 (male-to-female) (Fadlouallah *et al.*, 2015 and Ferlay *et al.*, 2021). As well as this, it has been suggested that gender differences reflect physiological differences; estrogens have been shown to protect women from gastric cancer (Sheh *et al.*, 2011 and Derakhshan *et al.*, 2009). According to a Korean Study (Shin *et al.*, 2011), no statistically significant differences were observed between the genders.

In our series, carcinoma was the most common histological form with 87.8% ;

several authors (Ntagirabiri *et al.*, 2013; Karimi *et al.*, 2014) have reported this. Based on the results of Chen *et al.*, 2016, 46.3% of cases had an intestinal type, 32.6% had a diffuse type, and 21.1% had a mixed type, according to Lauren's classification. Similar results were found in our series. Tang *et al.*, 2021 found that intestinal type was more prevalent than diffuse types (71.11% vs 28.9%). The majority of patients were diagnosed at advanced and metastatic stages (77.1%) of cancer, which is consistent with data provided by (Togo *et al.*, 2011). Moreover, 22 patients (17.8%) presented with distant metastases, including two patients (1.5%) that had two sites of metastasis. Early detection rates of gastric cancer (relatively curable) have exceeded 70% in Japan as a result of gastric cancer screening programs, where gastric cancer incidence is still high (Yashima *et al.*, 2022).

According to the findings of a recent Moroccan study by Amrani Hassani Joutei *et al.*, 2020 local lymph node invasion occurs at approximately equal rates at N0, N1, N2, and N3, respectively (27.55%, 26.53%, 26.53%, 19.39%), which is in agreement with our findings.

The majority of patients in our study [100] (76.3%) suffer from epigastralgia, as well as those in other series (44.4% to 100%) (Sano *et al.*, 2004; Meyer *et al.*, 2002). In our study (71%) [93] patients suffered from vomiting. This is a significant difference from the 17.5% and 20% rates reported by Hosseini *et al.*, 2007 and Heise *et al.*, 2009 respectively. This difference could be explained by the high frequency of advanced-stage antral tumors in our series.

Antropyloric regions were most affected in the present study (46.6%) followed by fundus regions (32.8%). These data are very similar to those reported by two studies (Togo *et al.*, 2011) and (Amegbor *et al.*, 2008). According to Layke & Lopez, 2004 *Helicobacter pylori* infection is associated with a high antropyloric localization. 38.2% of the cases had atrophic chronic gastritis as a precancerous lesion, while 16.8% had acute or chronic gastritis. As illustrated in Correa's diagram 1992, infection with *H. pylori* causes gastritis, which, after several years of chronic evolution, can progress to gastric carcinoma in up to 2% of patients.

In our study, we found a similar percentage of gastric ulcers (22.9%) as Bouglouga *et al.*, 2015, but not Fehim *et al.*, 2017, who found 58.8%. The history of partial gastrectomy is considered as risk factor for gastric stump cancers 10-15 years after surgery (Takeno *et al.*, 2014). In our study, we found 2.3% of partial gastrectomy stumps, similar to those reported by Fehim *et al.*, 2017.

In addition, several studies indicate that 10% of gastric cancer cases are inherited (Lv *et al.*, 2021). We found in this study that 7.6% of our patients had a family history of gastric cancer. In 1994, the International Agency for Research on Cancer recognized *Helicobacter pylori* as the first bacterium associated with cancer pathology. Our findings revealed that 41.99% of patients were positive for *H. pylori* infection and 30.53 % were smokers. Numerous meta-analyses suggest that individuals with *H. pylori* are more likely to develop gastric cancer compared to the control group (Holmes *et al.*, 2021).

In numerous studies, smoking has been demonstrated to contribute to stomach cancer development (Poorolajal *et al.*, 2020; Li *et al.*, 2019). However, a study by Butt *et al.*, 2019 found that current smoking was associated with a higher risk of gastric cancer, but only in individuals seropositive for *H. pylori*.

A reduction in gastric cancer risk can be achieved by eliminating *H. pylori* from the first-degree relatives of subjects with the disease, as well as from those with atrophic gastritis. *H. pylori* eradication also appears to reduce the risk of gastric carcinoma in individuals with gastritis and non-atrophic gastritis. However, more research is needed to determine the ideal treatment strategy to prevent the development of gastric cancer in these groups.

Our study found that 9.16% of our patients consumed alcohol or had previously consumed alcohol. Alcohol consumption has been shown to increase the risk of stomach cancer (Tramacere *et al.*, 2012). In a meta-analysis conducted by Ma *et al.*, 2017, even lower levels of alcohol consumption can increase the risk of gastric cancer. Furthermore, more recent studies indicate that alcohol-induced DNA damage may play an important role in the pathogenesis of gastric carcinogenesis, which may explain the increased risk for disease associated with excessive alcohol intake (Seitz *et al.*, 2007; Zhang *et al.*, 2018).

CONCLUSION

The most common histological type of gastric cancer is carcinoma. It is more prevalent in males than in females. Several factors contributed to the development of this carcinoma, the most significant of which was the infection with *Helicobacter pylori* and the smoking of cigarettes. A person with gastric carcinoma is frequently diagnosed at a late stage with a poor prognosis, thereby minimizing the likelihood that it can be successfully treated. Prevention and early detection should continue to be priorities.

Acknowledgements: We would like to thank the staff of the Anti-Cancer Center in Sidi Bel

Abbes for their invaluable support, guidance, and educational insight.

Conflicts of Interest: The authors have no conflicts of interest to declare.

REFERENCES

- Amegbor, K., Napo-Koura, G. A., Songne-Gnamkoulamba, B., Redah, D., & Tekou, A. (2008). Epidemiological and pathological aspects of gastrointestinal tumors in Togo. *Gastroenterologie Clinique et Biologique*, 32(4), 430–434. <https://doi.org/10.1016/j.gcb.2007.09.003>
- Amrani Hassani Joutei, H., Mahfoud, W., Sadaoui, I., Fechtali, T., & Benomar, H. (2020). Study of epidemiological clinical and pathological characteristics of gastric adenocarcinoma in a Moroccan population. *Annales de Pathologie*, 40(6), 442–446. <https://doi.org/10.1016/j.annpat.2020.04.014>
- Behar, D., Boublenza, L., Chabni, N., Hassaine, H., Dahmani, B., Masdoua, N., Nahet, A., & Meguenni, K. (2021). Retrospective epidemiological study on stomach cancer in a region of western Algeria: about 394 cases between 2011 and 2015. *Journal of Gastrointestinal Cancer*, 52(2), 706–710. <https://doi.org/10.1007/s12029-020-00459-z>
- Bouglouga, O., Lawson-Ananissou, L. M., Bagny, A., Kaaga, L., & Amegbor, K. (2015). Stomach cancer: Epidemiological, clinical and histological aspects at the Lome Campus teaching hospital (Togo). *Medecine et sante tropicales*, 25(1), 65–68. <https://doi.org/10.1684/mst.2014.0415>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>
- Butt, J., Varga, M. G., Wang, T., Tsugane, S., Shimazu, T., Zheng, W., Abnet, C. C., Yoo, K. Y., Park, S. K., Kim, J., Jee, S. H., Qiao, Y. L., Shu, X. O., Waterboer, T., Pawlita, M., & Epplein, M. (2019). Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea. In *Cancer Prevention Research* (Vol. 12, Issue 10, pp. 667–674). American Association for Cancer Research Inc. <https://doi.org/10.1158/1940-6207.CAPR-19-0238>
- Chen, Y. C., Fang, W. L., Wang, R. F., Liu, C. A., Yang, M. H., Lo, S. S., Wu, C. W., Li, A. F. Y., Shyr, Y. M., & Huang, K. H. (2016). Clinicopathological Variation of Lauren Classification in Gastric Cancer. *Pathology and Oncology Research*, 22(1), 197–202. <https://doi.org/10.1007/s12253-015-9996-6>
- Correa, P. (1992). Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Research*, 52(24), 6735–6740. <https://pubmed.ncbi.nlm.nih.gov/1458460/>
- Derakhshan, M. H., Liptrot, S., Paul, J., Brown, L., Morrison, D., & McColl, K. E. L. (2009). Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. *Gut*, 58(1), 16–23. <https://doi.org/10.1136/gut.2008.161331>
- Elghali, M. A., Gouader, A., Bouriga, R., Mahjoub, M., Jarrar, M. S., Ziadi, S., Mokni, M., Hamila, F., & Ltaeif, R. (2018). Gastric adenocarcinomas in central Tunisia: Evolution specificities through two decades and relation with Helicobacter pylori. *Oncology*, 95(2), 121–128.

- <https://doi.org/10.1159/000488488>
- Fadlouallah, M., Krami, H., Errabih, I., Benzoubeir, N., Ouazzani, L., & Ouazzani, H. (2015). Gastric cancer: Epidemiological aspects in Morocco. *Journal Africain Du Cancer*, 7(1), 8–15. <https://doi.org/10.1007/s12558-014-0322-4>
- Fehim, S., Bouhaous, R., Diaf, M., Drici, A. M., & Khaled, M. B. (2017). Epidemiological profile of gastric cancer in the northwestern region of Algeria: About 116 cases. *Journal of Gastrointestinal Oncology*, 8(4), 659–664. <https://doi.org/10.21037/jgo.2017.06.02>
- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. *International Journal of Cancer*, 149(4), 778–789. <https://doi.org/10.1002/ijc.33588>
- Heise, K., Bertran, E., Andia, M. E., & Ferreccio, C. (2009). Incidence and survival of stomach cancer in a high-risk population of Chile. *World Journal of Gastroenterology*, 15(15), 1854–1862. <https://doi.org/10.3748/wjg.15.1854>
- Holmes, L., Jr, Rios, J., Berice, B., Benson, J., Bafford, N., Parson, K., & Halloran, D. (2021). Predictive effect of *Helicobacter pylori* in gastric carcinoma development: Systematic review and quantitative evidence synthesis. *Medicines (Basel, Switzerland)*, 8(1), 1. <https://doi.org/10.3390/medicines8010001>
- Hosseini, S. N., Mousavinasab, S. N., Moghimi, M. H., & Fallah, R. (2007). Delay in diagnosis and treatment of gastric cancer: from the beginning of symptoms to surgery--an Iranian study. *The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology*, 18(2), 77–81. <https://pubmed.ncbi.nlm.nih.gov/17602354/>
- Hussein, W. M., Anwar, W. A., Attaleb, M., Mazini, L., Försti, A., Trimbitas, R. D., & Khyatti, M. (2016). A review of the infection-associated cancers in North African countries. In *Infectious Agents and Cancer* (Vol. 11, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s13027-016-0083-8>
- Karimi, P., Islami, F., Anandasabapathy, S., Freedman, N. D., & Kamangar, F. (2014). Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. In *Cancer Epidemiology Biomarkers and Prevention* (Vol. 23, Issue 5, pp. 700–713). American Association for Cancer Research Inc. <https://doi.org/10.1158/1055-9965.EPI-13-1057>
- Layke, J. C., & Lopez, P. P. (2004). Gastric cancer: diagnosis and treatment options. *American Family Physician*, 69(5), 1133–1140. <https://pubmed.ncbi.nlm.nih.gov/15023013/>
- Li, W. Y., Han, Y., Xu, H. M., Wang, Z. N., Xu, Y. Y., Song, Y. X., Xu, H., Yin, S. C., Liu, X. Y., & Miao, Z. F. (2019). Smoking status and subsequent gastric cancer risk in men compared with women: A meta-analysis of prospective observational studies. *BMC Cancer*, 19(1). <https://doi.org/10.1186/s12885-019-5601-9>
- Lv, L., Liang, X., Wu, D., Wang, F., Zhang, Y., Cang, H., Deng, X., & Li, M. (2021). Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer. *Journal of Cancer*, 12(8), 2385–2394. <https://doi.org/10.7150/JCA.51433>
- Ma, K., Baloch, Z., He, T.-T., & Xia, X. (2017). Alcohol consumption and gastric cancer risk: A meta-analysis. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 23, 238–246. <https://doi.org/10.12659/msm.899423>

- Matsuoka, T., & Yashiro, M. (2018). Biomarkers of gastric cancer: Current topics and future perspective. *World Journal of Gastroenterology: WJG*, 24(26), 2818–2832. <https://doi.org/10.3748/wjg.v24.i26.2818>
- Meyer, C., Lozac'h, P., Rohr, S., Topar, P., Youssef, C., & French Association of Surgery. (2002). Gastric cancer: the French survey. *Acta Gastro-Enterologica Belgica*, 65(3), 161–165. <https://pubmed.ncbi.nlm.nih.gov/12420608/>
- Nagini, S. (2012). Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. *World Journal of Gastrointestinal Oncology*, 4(7), 156. <https://doi.org/10.4251/wjgo.v4.i7.156>
- Ntagirabiri, R., Mumana, A., Marerwa, G., Nifasha, A., & Ntunzwenimana, T. (2013). Cancer et lésions précancéreuses gastriques au Burundi. *Journal Africain d'Hepato-Gastroenterologie*, 7(3), 130–133. <https://doi.org/10.1007/s12157-013-0468-x>
- Poorolajal, J., Moradi, L., Mohammadi, Y., Cheraghi, Z., & Gohari-Ensaf, F. (2020). Risk factors for stomach cancer: a systematic review and meta-analysis. *Epidemiology and Health*, 42, e2020004. <https://doi.org/10.4178/epih.e2020004>
- Sano, T., Sasako, M., Yamamoto, S., Nashimoto, A., Kurita, A., Hiratsuka, M., Tsujinaka, T., Kinoshita, T., Arai, K., Yamamura, Y., & Okajima, K. (2004). Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 22(14), 2767–2773. <https://doi.org/10.1200/JCO.2004.10.184>
- Seitz, H. K., & Becker, P. (2007). Alcohol metabolism and cancer risk. *Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism*, 30(1), 38–41, 44–47. <https://pubmed.ncbi.nlm.nih.gov/17718399/>
- Sheh, A., Ge, Z., Parry, N. M. A., Muthupalani, S., Rager, J. E., Raczynski, A. R., Mobley, M. W., McCabe, A. F., Fry, R. C., Wang, T. C., & Fox, J. G. (2011). 17 β -estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in helicobacter Pylori-infected INS-GAS male mice. *Cancer Prevention Research*, 4(9), 1426–1435. <https://doi.org/10.1158/1940-6207.CAPR-11-0219>
- Shin, A., Kim, J., & Park, S. (2011). Gastric cancer epidemiology in Korea. In *Journal of Gastric Cancer* (Vol. 11, Issue 3, pp. 135–140). <https://doi.org/10.5230/jgc.2011.11.3.135>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Takeno, S., Hashimoto, T., Maki, K., Shibata, R., Shiwaku, H., Yamana, I., Yamashita, R., & Yamashita, Y. (2014). Gastric cancer arising from the remnant stomach after distal gastrectomy: a review. *World Journal of Gastroenterology: WJG*, 20(38), 13734–13740. <https://doi.org/10.3748/wjg.v20.i38.13734>
- Tang, D., Ni, M., Zhu, H., Cao, J., Zhou, L., Shen, S., Peng, C., Lv, Y., Xu, G., Wang, L., & Zou, X. (2021). Differential prognostic implications of gastric adenocarcinoma based on

- Lauren's classification: a Surveillance, Epidemiology, and End Results (SEER)-based cohort study. *Annals of Translational Medicine*, 9(8), 646–646. <https://doi.org/10.21037/atm-20-7953>
- Togo, A., Diakit , I., Togo, B., Coulibaly, Y., Kant , L., Demb l , B. T., Traor , A., Traor , C., Kanout , M., & Diallo, G. (2011). Cancer gastrique au CHU Gabriel-Tour : Aspects  pid miologique et diagnostique. *Journal Africain Du Cancer*, 3(4), 227–231. <https://doi.org/10.1007/s12558-011-0167-8>
- Tramacere, I., Negri, E., Pelucchi, C., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Corrao, G., la Vecchia, C., & Boffetta, P. (2012). A meta-analysis on alcohol drinking and gastric cancer risk. In *Annals of Oncology* (Vol. 23, Issue 1, pp. 28–36). Oxford University Press. <https://doi.org/10.1093/annonc/mdr135>
- Yashima, K., Shabana, M., Kurumi, H., Kawaguchi, K., & Isomoto, H. (2022). Gastric Cancer Screening in Japan: A Narrative Review. In *Journal of Clinical Medicine* (Vol. 11, Issue 15). MDPI. <https://doi.org/10.3390/jcm11154337>
- Zhang, Y., Wu, H., Yang, F., Ning, J., Li, M., Zhao, C., Zhong, S., Gu, K., & Wang, H. (2018). Prognostic value of the expression of DNA repair-related biomarkers mediated by alcohol in gastric cancer patients. *The American Journal of Pathology*, 188(2), 367–377. <https://doi.org/10.1016/j.ajpath.2017.10.010>